Zentalis Pharmaceuticals Inc.

News & Events

Press Releases

In The Media

1. Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

   GlobeNewswire JUN 2, 2025 5:00 PM EDT
   SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL),...
   READ ARTICLE

2. Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress

   GlobeNewswire MAY 14, 2025 4:05 PM EDT
   First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ P...
   READ ARTICLE

3. Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

   GlobeNewswire MAY 1, 2025 5:00 PM EDT
   SAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), ...
   READ ARTICLE

4. Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC

   GlobeNewswire APR 28, 2025 8:00 AM EDT
   Phase 2 registration-intent trial enrolling Part 2a dose confirmation arms Topline data f...
   READ ARTICLE

5. Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting

   GlobeNewswire APR 23, 2025 4:05 PM EDT
   SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ...
   READ ARTICLE

6. Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

   GlobeNewswire APR 1, 2025 5:30 PM EDT
   SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ...
   READ ARTICLE

7. Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates

   GlobeNewswire MAR 26, 2025 4:05 PM EDT
   Positive azenosertib clinical data demonstrated clinically meaningful results in patients with Cy...
   READ ARTICLE

8. Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025

   GlobeNewswire MAR 25, 2025 4:40 PM EDT
   One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to me...
   READ ARTICLE

9. Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer

   GlobeNewswire MAR 15, 2025 11:25 AM EDT
   Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1...
   READ ARTICLE

10. Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire MAR 3, 2025 5:00 PM EST
    SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ...
    READ ARTICLE